The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever.

[familial mediterranean fever]

To examine the effect of rilonacept on the health-related quality of life (HRQoL ) in patients with poorly controlled familial Mediterranean fever (FMF ).As part of a randomized , double -blinded trial comparing rilonacept and placebo for the treatment of FMF , patients /parents completed the modified Child Health Questionnaire (CHQ ) at baseline , and at the start and end of each of 4 treatment courses , 2 each with rilonacept and placebo .Fourteen subjects were randomized ; mean age was 24 .4 ± 11 .8 years . At baseline the physical HRQoL score was significantly less (24 .2 ± 49 .5 ) but the psychosocial score was similar to the population norm (49 .5 ± 10 .0 ). There were significant improvements in most HRQoL concepts after rilonacept but not placebo . Significant differences between rilonacept and placebo were found in the physical (33 .7 ± 16 .4 versus 23 .7 ± 14 .5 , P = 0 .021 ) but not psychosocial scores (51 .4 ± 10 .3 versus 49 .8 ± 12 .4 , P = 0 .42 ). The physical HRQoL was significantly impacted by the treatment effect and patient global assessment .Treatment with rilonacept had a beneficial effect on the physical HRQoL in patients with poorly controlled FMF and was also significantly related to the patient global assessment . This trial is registered with ClinicalTrials .gov Identifier NCT 00582907 .

Diseases
Validation

Diseases presenting "global assessment" symptom

familial mediterranean fever

You can validate or delete this automatically detected symptom